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Aim: We examined ethnicity-related differences in the uptake of a temporary free-of-charge HPV vaccine
(HPVV) catch-up programme offered in Denmark from August 2012 to December 2013 to women born
from 1985–1992 and compared it with the previous self-payment system in place.
Methods: We conducted a nationwide retrospective cohort study. We performed logistic regression
analyses to examine the relationship between ethnic background and HPV vaccine (HPVV) programme
initiation.
Results: The free programme increased the vaccination uptake from 16% to 75%. Descendants (Denmark-
born womenwith both parents of foreign origin) and immigrants in Denmark for more than 5 years were
less likely to initiate the free HPVV programme than Denmark-born women ((aOR¼0.56; 95% CI: 0.54–
0.59) and (aOR¼0.39; 95% CI: 0.38–0.40), respectively). The likelihood of HPVV programme initiation
among immigrants increased with time in Denmark ((aOR¼2.28; 95% CI: 2.11–2.48) for immigrants
living in Denmark for 16–20 years compared to 6–10 years)).
Conclusion: The initiation of the free-of-charge HPVV programme was satisfactory. However, large dif-
ferences in uptake were demonstrated, indicating that some target groups are harder to reach than
others. The integration process (as related to use of health services) occurs over many years where
differences between the different population groups seem to vanish.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Between 2006 and 2013, two HPV vaccines (HPVV) have been
licensed globally, aimed at preventing cervical cancer: Cervarixs, a
bivalent vaccine that targets papillomavirus 16 and 18, and Gar-
dasils, which additionally targets papillomavirus 6 and 11 [1].
Additionally, a nine-valent vaccine that targets ﬁve additional
papillomavirus (types 31,33,45,52,53) has been licensed by EMA in
2015 [2] and by FDA in 2014 [3]. WHO considers girls aged 9–13
years as the primary target group (routine group) to receive the
HPVV [4]. Some vaccination programmes target women up to 26B.V. This is an open access article u
emiology, Statens Serum In-
Denmark.
asadevante),
lita@gmail.com (J.G. Cuesta),years of age [5]. The highest rates of genital HPV infection are
found in women from 18 to 28 years of age [6]. Targeting ad-
ditionally older catch-up groups contributes to achieve higher
coverage rates and to accelerating the beneﬁts of the vaccine.
Moreover, some countries experience higher HPVV coverage rates
among catch-up than among routine groups [7].
Gardasils was introduced into the Danish standard childhood
vaccination programme in January 2009, aimed at girls aged 12
years. Additionally, a catch-up programme for girls aged 13–15
years had been in place lasting from October 2008 to the end of
2010 [8]. High general public support for introducing the HPVV in
Denmark, in particular from organisations such as the Danish
Cancer Society, resulted in the decision to also include women
between the ages of 19 and 28 years in a cost-free catch-up pro-
gramme lasting from 27 August 2012 to 31 December 2013 [9]
(Fig. 1).
This study focuses primarily on HPVV programme initiationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Timeline for HPV vaccination programme implementation in Denmark for
women born in 1985–1992.
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born between 1985 and 1992, and in particular on the role of ethnic
background as a determinant of HPVV programme initiation. We
have this particular focus as the literature suggests that ethnic
background inﬂuences HPVV uptake [10–15]. In Denmark, two
studies based on a cohort of girls born in 1996 [16] and 1996–1997
[17] respectively, revealed that ethnic Danish girls had a higher HPV
routine vaccination uptake than Non-Danes. Since Denmark is a
country with large ethnic minorities and immigrant populations, an
analysis is relevant in order to determine differences in HPV vac-
cination by ethnic background also among older cohorts. Second,
we compared this programme with the previous self-payment
system in place to assess whether the free-of-charge catch-up
programme had a particular effect on HPVV programme initiation
in speciﬁc ethnic groups, i.e. if the introduction of a free-of-charge
programme resulted in a different ethnic HPVV initiation proﬁle
when compared to initiation levels prior to the programme, when
the vaccination was subject to a self-payment of approximately
1350DKK/181€ per dose. This study provides the ﬁrst comprehen-
sive analysis of ethnicity-related differences in HPV vaccination in a
large cohort of women in Denmark born from 1985 to 1992.2. Methods
2.1. Data sources
We used the Danish Vaccination Registry (DDV) to conduct a
nationwide retrospective cohort study. Vaccination data and socio-
demographic variables were linked through the civil registration
number. All citizens residing in Denmark are registered with a
unique personal identiﬁer (CPR-number), where individual in-
formation such as name, gender, date of birth, vital status, country
of birth, citizenship and address is registered.
2.2. Study period
The temporary free-of-charge HPVV catch-up programme was
offered from August 27th 2012 to December 31st 2013 to all wo-
men born from 1985 to 1992 and registered as citizens in Den-
mark. The CPR-registry data was last updated in June 27th 2013,
six months before the catch-up programme concluded. Therefore,
women arriving in Denmark after this date were not included in
this study.2.3. Outcome variable
The outcome under study was the uptake of the ﬁrst dose of
the HPVV (HPV1) during the temporary free-of-charge catch up
programme among the cohort of women born from 1985 to 1992,
as well as prior to it, i.e. HPV1 uptake when the vaccine was
medically prescribed and subject to self-payment.
For the purpose of this study, only HPV vaccination initiation,
measured as the uptake of the ﬁrst HPVV dose out of the three
scheduled, was examined.
Data on HPV vaccines administered outside Denmark were not
available, the result being that women who have initiated the
vaccination programme outside Denmark were registered as non-
vaccinated. While this is not assumed to be a major concern for
most of the population under study, it is possible that there is an
overrepresentation of these cases among immigrants on short-
term stays in Denmark (e.g. students), particularly if they have a
similar level of access to the vaccine in their home countries.
Therefore, women living in Denmark for less than 6 years from the
end of the free-of-charge vaccination programme were removed
from the logistic regression models, assuming that the number of
women in this age group vaccinated against HPV by December
31st 2007 in their countries of origin is low.2.4. Predictor variables
The variables under study were all socio-demographic variables
registered in the CPR-registry that either provide a measure of
ethnicity or are shown to be related to the uptake of the HPVV
[10,16,18–24].
2.4.1. Main predictor variable
 Ethnic background, categorised into four groups according to
women’ and parents’ country of origin: Denmark-born women
with both parents Denmark-born, Denmark-born women with
one parent Denmark-born, Denmark-born women with both
parents of foreign origin (descendants) and women of foreign
origin (immigrants). For descendants, further divisions were
made by grouping women according to parents’ region/country
of origin. Immigrants were also further categorized according to
their region/country of origin.
Countries with a representative population of 800 women or
more were categorized independently, and countries with smaller
populations were grouped together according to region of origin.
2.4.2. Other predictor variables (control variables)
 Year of birth: women were categorized in eight groups by year
of birth, from 1985 to 1992.
 Civil status: Women were divided into two categories: Married,
which includes married women and women in a registered
partnership, and not married, which accounts for single, di-
vorced, widows and women whose registered partnership
ﬁnished.
 Area of residence: based on their address, the women were
grouped in eleven speciﬁc areas of residence in Denmark.
 Years lived in Denmark: The years spent in Denmark were
grouped in periods of ﬁve years, except from the last category in
which 8 years were grouped together (6–10 years, 11–15 years,
16–20, 21–28 years).
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First, descriptive analyses were conducted to calculate HPVV
initiation both during and before the launch of the free-of-charge
catch-up programme. Then, univariable logistic regression was
performed to investigate any association between each of the so-
cio-demographic variables and HPV1 uptake. Variables displaying
signiﬁcance in the univariable analysis were included in the
multivariable model and logistic regression was conducted. All
data cleaning, management and analysis were done using the
statistical software package STATA 12.
2.6. Ethical considerations
No ethical approval was needed for this study since it is a
register based study and thus does not involve human subjects or
human biological material such as tissue, ovums or cells [25]. The
study was notiﬁed to the Danish data protection agency under the
record number 2008-54-0474.3. Results
A total of 274,154 women born from 1985 to 1992 were regis-
tered in the CPR-system until June 27th 2013. Of these, 44,122
women had already initiated the HPV vaccination programme
before the free-of-charge programme was launched, i.e. when it
was subject to self-payment, representing a 16.1% of the total
population. Subsequently, the remaining 230,032 women born
between 1985 and 1992 could have initiated the free-of-charge
HPVV programme. Of these, 158,380 (68.9%) were ethnic Danish
women with both parents Denmark-born, 13,957 (6.1%) were
ethnic Danish women with one parent Denmark-born, 9314 (4.0%)
were Denmark-born women of foreign descent (descendants) and
immigrant women represented one ﬁfth (20.8%) of the cohort
under study (47,790 out of 230,032 women).
In terms of ethnic background, Denmark-born women with
both parents Denmark-born had the highest HPV1 uptake (79.7%)
in the free-of-charge HPVV programme, followed by Denmark-
born women with one Denmark-born parent (75.7%), and des-
cendants (65.9%). Meanwhile, overall HPV1 uptake was lower
among immigrants (39.0%), being around half of the uptake among
ethnic Danes. After excluding the immigrant population living in
Denmark for less than six years from the end of the free-of-charge
programme, the uptake of HPV1 in this group was 58.9%. Fig. 2
shows the HPV1 coverage during the free-of-charge programme
and prior to it (subject to self-payment) in the main populations in
the cohort after excluding immigrants in Denmark for less than six
years from December 31st 2013.
A descriptive overview of HPV1 coverage in the whole cohort
(N¼274,154) before and after the introduction of the cost-free7.16
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Fig. 2. HPV1 coverage by population group. The immigrant population living in
Denmark for less than 6 years has been excluded.programme showed that the launch of the temporary free-of-
charge catch-up programme served to raise total HPV1 coverage
from 16.0% to 75.1%, and to decrease the relative difference in
uptake between ethnic Danish women and non-Danish women for
most of the minority groups. Descendants and immigrants con-
stituted the low-uptake groups prior to the programme. With the
introduction of the programme, there was a 12-fold increase in
uptake percentage among descendants and an 11-fold increase in
uptake percentage among immigrants. In comparison, a relatively
smaller four-fold increase was observed for Denmark-born women
with two parents Denmark-born, while there was a ﬁve-fold in-
crease among Denmark-born women with one parent Denmark-
born. If immigrants in Denmark for less than 6 years were ex-
cluded, total HPV1 coverage raised from 17.8% to 80.7%, and there
was an 8-fold increase in uptake percentage among immigrants.
Although HPV1 coverage for some low-uptake groups still re-
mained low, the introduction of the free-of charge programme
contributed to lift coverage among these groups, creating a slightly
more equal total coverage proﬁle. (Table 1).
Table 2 shows crude and adjusted results for the association
between region of origin and the initiation of the free-of-charge
programme. Descendants from East Asia were the most likely to
initiate the programme, the likelihood being higher than for the
reference group (Denmark-born women with two parents Den-
mark-born). Descendants with origin in Central-Eastern Europe
were more likely than descendants of the MENA-PAT (Middle-East,
North-Africa, Pakistan, Afghanistan and Turkey) region to start the
programme. Immigrants from the Indian Subcontinent, other
Nordic countries and East Asia were the most likely to initiate the
HPVV programme, whereas immigrants from Oceania, North
America and Sub-Saharan Africa were the least likely. (Table 2).
HPV1 coverage was higher among immigrants who have lived
in Denmark for a greater number of years. For instance, HPV1
coverage was 69.6% for immigrants living in Denmark for 21–28
years, 65.3% for immigrants in Denmark for 16–20 years, and 59.3%
and 43.2% for immigrants in Denmark for 11–15 years and 6–10
years, respectively. Similarly, immigrants living in Denmark for
longer periods of time were the most likely to initiate the HPVV
programme (aOR¼2.88; 95% CI: 2.67–3.12 for those who have
lived in Denmark for 21–28 years compared to those living in the
country for 6–10 years, which form the reference group). Im-
migrants living in Denmark for 16–20 years were more than twice
as likely to initiate the free-of-charge programme as the reference
group, and immigrants in Denmark for 11–15 years were also more
likely than the reference group to initiate it (aOR¼1.77; 95% CI:
1.63–1.93).
Comparing adjusted likelihoods of initiating the HPVV pro-
gramme prior to and during the free-of-charge catch-up pro-
gramme, a considerable increase in vaccination likelihood was
seen, relative to ethnic Danes, for women of most countries in the
free-of-charge programme (Table 3). This is particularly the case
for descendants from Pakistan and Lebanon, and for immigrants
from Afghanistan, Somalia and Iraq. At the same time, no clear
increase relative to ethnic Danes was seen among immigrants
from other Western European countries or the USA.4. Discussion
4.1. Main ﬁndings
Ethnic Danish womenwere the most likely group to initiate the
HPVV programme. Overall, there was signiﬁcant variation in HPVV
programme initiation among descendant and immigrants from
different regions and countries, both during and prior to the cost-
free programme. The number of years lived in Denmark was found
Table 1
Impact of the free-of-charge HPV vaccination programme in the main descendant and immigrant populations under study. Descriptive results for HPV1 uptake percentage
before (vaccine subject to self-payment), during the free-of-charge programme, and in total.
Variables Vaccination coverage in the whole cohort (%) Vaccination coverage in the cohort after excluding the immigrant population
living in Denmark for less than 6 years (%)
N HPV1 HPV1 HPV1 N HPV1 HPV1 HPV1
(Before) (Programmea) (Total) (Before) (Programmea) (Total)
Number of doses/total
population
44,122/
274,154
161,819/230,032 205,941/
274,154
44,045/247,381 155,613/203,336 199,658/247,381
Country of origin
Denmark (Dk)- born w
2 parents Dk-born
197,415 19.8 79.7 83.7 (Same numbers as vaccination coverage in the column for the whole cohort. See left
side of the table)
Dk-born w one parent Dk-
born
16,780 16.8 75.7 79.8
Descendantsb 9860 5.5 65.9 67.7
Turkey 3469 4.6 61.8 67.1
Pakistan 1014 2.0 57.8 58.6
Lebanon 956 3.4 65.6 63.1
Immigrants 49,495 3.4 39.0 41.1 22,722 7.16 58.87 61.82
Norway 2572 3.5 55.3 56.9 802 10.4 67.7 71.1
Sweden 1655 4.9 51.6 54.0 761 9.7 63.9 67.4
Faroe Islands 1349 4.5 72.7 73.9 767 6.8 75.4 77.1
Greenland 1020 6.6 63.3 65.7 993 6.3 63.1 65.5
Germany 2394 3.3 24.5 26.9 900 8.6 48.9 53.2
Spain 895 2.0 15.3 17.0 137 13.1 44.5 51.8
France 832 3.3 11.8 14.7 168 14.9 40.6 49.4
USA 1,04 7.1 21.8 27.4 387 18.4 51.0 60.0
Poland 2817 0.9 26.7 27.3 847 2.6 42.2 43.7
Rumania 2372 1.0 18.2 19.0 338 6.5 40.5 44.4
Lithuania 1624 0.6 22.4 22.8 298 2.7 41.0 42.6
Bosnia-Herzegovina 1394 6.1 67.0 69.0 1321 6.4 69.2 71.2
Latvia 814 0.9 22.7 23.3 133 2.3 39.2 40.6
Ukraine 1183 0.9 23.6 24.2 300 3.7 45.3 47.3
The Philippines 2554 0.5 25.7 26.0 291 3.4 57.3 58.8
China 1358 1.6 40.0 41.0 497 4.0 56.4 58.2
South Korea 980 17.1 70.8 75.8 848 19.5 80.1 84.0
India 851 12.8 50.5 56.9 498 21.7 79.2 83.7
Iraq 1692 1.3 55.2 55.8 1565 1.4 56.8 57.4
Afghanistan 1220 1.6 65.4 65.9 1006 1.9 68.3 68.9
Turkey 1076 2.0 40.3 41.5 721 2.8 48.9 50.4
Somalia 959 0.4 31.6 31.9 811 0.5 34.9 35.3
a Vaccination coverage during the the free-of-charge programme (27/08/2012 to 31/12/2013) after removing from the total population every woman that received any
dose of the vaccine prior to the free-of-charge programme.
b Descendants: Denmark-born women with both parents Denmark-born.
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migrants, with a greater number of years associated with higher
likelihood of starting the programme. Finally, it was found that
while descendants and immigrants remained less likely than
ethnic Danes to start HPVV programme also during the cost-free
programme, the introduction of the programme contributed to a
relatively greater lift in coverage among these groups.
4.2. Findings in relation to other studies
Our results are in accordance with a number of published
studies showing that the majority ethnic population of a country is
more likely to initiate a HPVV programme than minority groups in
the same country [10–12,14,16,26]. Beyond ethno-cultural reasons
for non-participation that might affect ethnic majority and min-
ority population to a greater or lesser extent, ethnic minorities face
speciﬁc barriers compared to ethnic Danish groups. For instance,
immigrants may be unfamiliar with the Danish healthcare system
and may face a language barrier in the access to medical services
[24]. A study conducted in the Netherlands [27] revealed, ad-
ditionally, that communication between general practitioners and
immigrants was different compared to communication with the
ethnic majority population; the time of communication was
shorter, with a verbal predominance of the doctor over the patient,and a poor mutual understanding often leading to a less de-
manding patient and lower compliance. In addition, differences in
HPVV programme participation among the immigrant population
might be partly explained by the reasons for migration. Denmark
hosts a great number of workers from the new European Union
member states to work in the construction, consumer industry,
agriculture, or cleaning, with potentially lower wages than the
Danish average income [28]. This type of migration might affect
their possibilities of integration in the country, inﬂuencing their
knowledge about for instance healthcare services [24], which may
explain the low HPVV programme initiation among some of these
speciﬁc minority populations.
The results in this study reveal that the introduction of the
cost-free programme served to markedly increase total HPV1
coverage, especially lifting coverage among certain descendants
and immigrants groups. One study [29] analysing equality in the
use of healthcare services in Denmark reveal that, in general, non-
Western descendants and immigrants are more likely than ethnic
Danes to use free-of-charge healthcare services. However, reduced
likelihoods among them are seen when it comes to visiting the
dentist, which in Denmark requires co-payment, despite adjusting
for the effect of socio-economic status [29]. This may be seen to
indicate a low willingness among immigrants and descendants to
pay for medical services and can be interpreted to explain why the
Table 2
Association between region of origin and free-of-charge HPV vaccine programme initiation after removing from the model the immigrant population living in Denmark for
less than 6 years.
Variables Vaccination initiation Vaccination initiation
CRUDE ADJUSTEDa
Odds
Ratio
P-value [95%
Conf.
Interval] Odds
Ratio
P-value [95%
Conf.
Interval]
Region of origin
Denmark (Dk)-born w 2 parents Dk-born Ref. Ref.
Dk-born w one parent Dk-born 0.79 o0.0001 0.76 0.82 0.83 o0.0001 0.80 0.87
Descendants
Other Nordic countries 0.76 0.131 0.53 1.086 0.84 0.361 0.59 1.21
Greenland 0.20 0.001 0.08 0.52 0.20 0.001 0.08 0.52
Other West. Eur. Countries 0.46 o0.0001 0.33 0.65 0.49 o0.0001 0.35 0.69
North America – – – – – – – –
Oceania – – – – – – – –
Central Eastern Eur, 0.54 o0.0001 0.46 0.62 0.63 o0.0001 0.54 0.73
Former USSR 0.25 0.093 0.05 1.26 0.30 0.138 0.06 1.47
Lat. Amer. & Caribb. 1.52 0.435 0.53 4.40 1.81 0.274 0.63 5.22
East Asia 1.37 0.012 1 1.76 1.47 0.002 1.15 1.88
Indian Subcontinent 0.76 0.013 0.61 0.94 0.75 0.013 0.60 0.94
MENA-PATb 0.44 o0.0001 0.42 0.46 0.51 o0.0001 0.48 0.54
Sub-Saharan Africa 0.53 o0.0001 0.38 0.73 0.61 0.003 0.44 0.85
Immigrants
Other Nordic Countries 0.55 o0.0001 0.51 0.60 0.60 o0.0001 0.55 0.65
Greenland 0.43 o0.0001 0.38 0.50 0.43 o0.0001 0.37 0.49
Other West. Eur. Countries 0.29 o0.0001 0.27 0.32 0.30 o0.0001 0.28 0.33
North America 0.24 o0.0001 0.20 0.29 0.26 o0.0001 0.21 0.32
Oceania 0.12 o0.0001 0.08 0.16 0.12 o0.0001 0.09 0.17
Central and East. Eur. 0.30 o0.0001 0.28 0.32 0.31 o0.0001 0.29 0.33
Former USSR 0.28 o0.0001 0.24 0.32 0.31 o0.0001 0.27 0.36
Latin America & Carib. 0.48 o0.0001 0.41 0.57 0.51 o0.0001 0.43 0.60
East Asia 0.52 o0.0001 0.47 0.56 0.56 o0.0001 0.52 0.61
Indian Subcontinent 0.64 o0.0001 0.55 0.75 0.68 o0.0001 0.58 0.80
MENA-PATb 0.35 o0.0001 0.33 0.37 0.38 o0.0001 0.36 0.40
Sub-Saharan Africa 0.26 o0.0001 0.24 0.28 0.27 o0.0001 0.25 0.30
a Adjusted for year of birth, civil status and area of residence in Denmark (Number of observations in the model¼202,159).
b MENA-PAT¼Middle-East North-Africa-Pakistan, Afghanistan and Turkey.
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impact among immigrants and descendants.
4.3. Limitations
Undocumented migrants, refugees and asylum seekers may be
at high-risk of non-vaccination. However, they are not included in
the register and are therefore not part of the study. As explained
above, data on HPVV given outside Denmark were not retrieved.
However, this information bias has been minimised by excluding
immigrant women that have lived in Denmark for less than six
years by the end of the free-of-charge programme. There might be
an underreporting of vaccines administered, as general practi-
tioners and private companies are responsible for registering ad-
ministered vaccines. However, this potential bias is minimized as
reimbursement of vaccines is made on the basis of the registration
of the vaccine given. In addition, even if there is underreporting,
there is no reason to expect that the underreporting should vary
across the groups and variables that are compared in this study.
The variable socio-economic status is one possibly important
variable that is not included due to lack of accessible data.5. Conclusion
Women with non-Danish background are less likely to initiate
the HPVV programme than ethnic Danish women. Large differ-
ences in HPVV uptake are seen between different groups of des-
cendants and immigrants across countries and regions. Further-
more, for immigrants, the likelihood of initiating the catch-upprogramme increases with the number of years lived in Denmark.
Overall and for the large majority of groups, the relative difference
in ﬁrst vaccine dose coverage between ethnic Danish women and
non-Danish women was smaller following the free-of-charge
programme compared to the coverage prior to the self-payment
programme. This suggests that a cost-free programme has a po-
sitive impact in speciﬁc minority populations, helping to overcome
a possible economic barrier. However, signiﬁcant disparities in
HPVV uptake remain even after adjusting for the number of years
lived in Denmark.
Preventive health, in this case in terms of preventive HPV
vaccination, faces challenges that need to be addressed in order to
make preventive programmes more efﬁcient from a public health
perspective. Ensuring that doctors and patients are able to com-
municate effectively may be essential to increasing the participa-
tion of women in preventive health. Therefore, measures such as
increased use of translators or doctors with a similar language and
cultural background to large groups of immigrants in a particular
area could help to improve participation of hard to reach popu-
lations in future vaccination campaigns. However, the cost of such
measures in a universal healthcare system can be high, and cost-
effectiveness compared to other possible measures should ﬁrst be
analyzed. Furthermore, in order to promote health among all
ethnic groups, health intervention should take ethno-cultural
differences into consideration. This could include targeted
awareness campaigns in areas with a high concentration of ethnic
minority women, in media and institutions frequently used by
ethnic minorities, and, more generally, the use of posters or other
on-line campaign means that visibly promote the idea that health
promotion is for all ethnic groups in society.
Table 3
Association between country of origin and HPV vaccine programme initiation both before (subject to self-payment) and during the free-of-charge programme after excluding
the immigrant population living in Denmark for less than 6 years.
Variables Vaccination initiation Vaccination initiation
ADJUSTEDa ADJUSTEDa
(SELF-PAYMENTb) (FREE PROGRAMMEc)
Odds Ratio P-value [95% Conf. Interval] Odds Ratio P-value [95%Conf. Interval]
Country of origin
Denmark (Dk)-born with 2 parents Dk-born Ref. Ref.
Dk-born with 1 parent Dk-born 0.72 o0.0001 0.69 0.75 0.83 o0.0001 0.80 0.87
Descendants
Turkey 0.19 o0.0001 0.16 0.22 0.56 o0.0001 0.52 0.60
Pakistan 0.06 o0.0001 0.04 0.10 0.44 o0.0001 0.38 0.50
Lebanon 0.10 o0.0001 0.07 0.14 0.44 o0.0001 0.38 0.50
Immigrants
Norway 0.48 o0.0001 0.38 0.61 0.58 o0.0001 0.49 0.67
Sweden 0.42 o0.0001 0.33 0.54 0.49 o0.0001 0.42 0.58
Faroe Islands 0.31 o0.0001 0.23 0.41 0.83 0.031 0.70 0.98
Greenland 0.28 o0.0001 0.21 0.36 0.43 o0.0001 0.37 0.49
Germany 0.41 o0.0001 0.32 0.52 0.24 o0.0001 0.21 0.28
Spain 0.60 0.05 0.36 1.00 0.23 o0.0001 0.16 0.33
France 0.60 0.024 0.39 0.93 0.20 o0.0001 0.14 0.28
USA 0.78 0.067 0.60 1.02 0.29 o0.0001 0.23 0.36
Poland 0.15 o0.0001 0.10 0.23 0.20 o0.0001 0.17 0.23
Rumania 0.39 o0.0001 0.25 0.61 0.18 o0.0001 0.14 0.22
Lithuania 0.15 o0.0001 0.07 0.29 0.19 o0.0001 0.15 0.24
Bosnia-Herzegovina 0.31 o0.0001 0.24 0.38 0.57 o0.0001 0.51 0.65
Latvia 0.12 o0.0001 0.04 0.38 0.17 o0.0001 0.12 0.25
Ukraine 0.27 o0.0001 0.15 0.50 0.23 o0.0001 0.18 0.30
The Philippines 0.17 o0.0001 0.09 0.32 0.39 o0.0001 0.31 0.50
China 0.21 o0.0001 0.13 0.32 0.40 o0.0001 0.33 0.48
South Korea 1.15 0.117 0.97 1.37 1.08 0.426 0.89 1.30
India 1.20 0.10 0.97 1.50 1.00 0.999 0.78 1.28
Iraq 0.06 o0.0001 0.04 0.09 0.35 o0.0001 0.32 0.39
Afghanistan 0.07 o0.0001 0.05 0.12 0.56 o0.0001 0.49 0.64
Turkey 0.17 o0.0001 0.11 0.26 0.29 o0.0001 0.25 0.34
Somalia 0.02 o0.0001 0.01 0.05 0.14 o0.0001 0.12 0.16
a Adjusted for year of birth, civil status and area of residence in Denmark
b Number of observations in the model¼234,023
c Number of observations in the model¼190,974
V. Fernández de Casadevante et al. / Papillomavirus Research 2 (2016) 78–84 83A future research priority should be to explore how to increase
HPVV uptake among speciﬁc minority groups, as this study pro-
vides a solid indication of the key differences in HPVV initiation
between groups and suggests possible explanatory factors. Ad-
ditionally, conducting a similar quantitative study with relevant
socio-economic variables is recommended.Author contributions
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